Quantum Biopharma Ltd. Files November 2024 6-K Report
Ticker: QNTM · Form: 6-K · Filed: Nov 25, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Nov 25, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer, corporate-update
TL;DR
Quantum Biopharma (formerly FSD Pharma) filed its monthly 6-K, confirming 20-F annual report filings.
AI Summary
Quantum Biopharma Ltd. (formerly FSD Pharma Inc.) filed a Form 6-K on November 25, 2024. The company, incorporated in A6 and headquartered in Toronto, Canada, is in the Pharmaceutical Preparations industry. This filing is for the month of November 2024 and indicates the company will file annual reports under Form 20-F.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Quantum Biopharma Ltd.'s ongoing reporting status.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.
Key Numbers
- 001-39152 — SEC File Number (Identifies the company's filing history with the SEC)
Key Players & Entities
- Quantum Biopharma Ltd. (company) — Registrant
- FSD Pharma Inc. (company) — Former company name
- Donal Carroll (person) — Chief Financial Officer
- November 2024 (date) — Reporting period
- November 25, 2024 (date) — Filing date
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of November 2024.
What was Quantum Biopharma Ltd.'s former name?
Quantum Biopharma Ltd.'s former name was FSD Pharma Inc., with a date of name change on March 27, 2019.
Which annual report form does Quantum Biopharma Ltd. file?
Quantum Biopharma Ltd. files its annual reports under cover of Form 20-F.
Who signed this report on behalf of Quantum Biopharma Ltd.?
The report was signed by Donal Carroll, Chief Financial Officer, on November 25, 2024.
Where is Quantum Biopharma Ltd.'s principal executive office located?
The principal executive office is located at 55 University Ave., Suite 1003, Toronto, Ontario, M5J2H7, Canada.
Filing Stats: 140 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2024-11-25 07:22:44
Filing Documents
- fsd_6k.htm (6-K) — 9KB
- fsd_ex991.htm (EX-99.1) — 21KB
- 0001654954-24-014846.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: November 25, 2024 By: /s/ Donal Carroll Donal Carroll, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description Exhibit 99.1 Press Release 3